Kailera Therapeutics (NASDAQ:KLRA) Raised to Strong-Buy at TD Cowen

Posted by Brenda Bartman on May 13th, 2026

Kailera Therapeutics (NASDAQ:KLRA – Get Free Report) was upgraded by equities research analysts at TD Cowen to a “strong-buy” rating in a research note issued to investors on Tuesday,Zacks.com reports.

A number of other equities analysts have also recently commented on the company. Wall Street Zen raised Kailera Therapeutics to a “hold” rating in a report on Saturday, April 25th. Jefferies Financial Group began coverage on Kailera Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $48.00 price objective for the company. Evercore started coverage on Kailera Therapeutics in a research report on Tuesday. They issued an “outperform” rating for the company. William Blair started coverage on Kailera Therapeutics in a research report on Tuesday. They set an “outperform” rating for the company. Finally, JPMorgan Chase & Co. initiated coverage on Kailera Therapeutics in a research report on Tuesday. They set an “overweight” rating and a $30.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating and four have issued a Buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $42.75.

Read Our Latest Research Report on KLRA

Kailera Therapeutics Price Performance

NASDAQ KLRA opened at $22.30 on Tuesday. Kailera Therapeutics has a twelve month low of $20.86 and a twelve month high of $28.23.

Insider Transactions at Kailera Therapeutics

In other news, Director Andrew T. Kaplan bought 8,398,438 shares of the business’s stock in a transaction dated Monday, April 20th. The shares were acquired at an average price of $16.00 per share, for a total transaction of $134,375,008.00. Following the completion of the transaction, the director owned 26,255,581 shares of the company’s stock, valued at approximately $420,089,296. This trade represents a 47.03% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Adam Koppel purchased 1,562,500 shares of the stock in a transaction that occurred on Monday, April 20th. The shares were bought at an average cost of $16.00 per share, for a total transaction of $25,000,000.00. Following the acquisition, the director owned 22,583,268 shares of the company’s stock, valued at approximately $361,332,288. The trade was a 7.43% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders have bought 10,460,938 shares of company stock worth $167,375,008.

Kailera Therapeutics Company Profile

(Get Free Report)

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.